Yamashita, Tatsuya

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 2,479

A liver-derived secretory protein, selenoprotein P, causes insulin resistance

Misu, H., Takamura, T., Takayama, H., Hayashi, H., Matsuzawa-Nagata, N., Kurita, S., Ishikura, K., Ando, H., Takeshita, Y., Ota, T., et al. (2010) · Cell Metabolism

Adipokines, Inflammation, and Metabolic DiseasesSelenium in Biological Systems

Cited by 583

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 365

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

Yoshida, H., Shiratori, Y., Kudo, M., Shiina, S., Mizuta, T., Kojiro, M., Yamamoto, K., Koike, Y., Saito, K., Koyanagi, N., et al. (2011) · Hepatology

Vitamin K Research StudiesHepatocellular Carcinoma Treatment and Prognosis

Cited by 127

CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status

Ni, Y., Zhuge, F., Ni, L., Nagata, N., Yamashita, T., Mukaida, N., Kaneko, S., Ota, T., & Nagashimada, M. (2022) · Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 86

Effects of vasopressin V1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in response to oxytocin stimulation

Nakamura, K., Fujiwara, Y., Mizutani, R., Sanbe, A., Miyauchi, N., Hiroyama, M., Yamauchi, J., Yamashita, T., Nakamura, S., Mori, T., et al. (2008) · Endocrinology

Neuroendocrine regulation and behaviorNeuropeptides and Animal Physiology

Cited by 25

Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C

Honda, M., Nakamura, M., Tateno, M., Sakai, A., Shimakami, T., Shirasaki, T., Yamashita, T., Arai, K., Yamashita, T., Sakai, Y., et al. (2010) · Journal of Hepatology

Hepatitis C virus researchinterferon and immune responses

Cited by 21